pharma · Primary Biliary Cholangitis · Pyoderma Gangrenosum
Arena Pharmaceutical Enterprises Limited
PHARMACEUTICAL ENTERPRISES drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PHARMACEUTICAL ENTERPRISES drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L04) compound in PHARMACEUTICAL ENTERPRISES's portfolio. Molecular target: Sphingosine 1-phosphate receptor 1.